CLYM
Climb Bio, Inc.
NASDAQ · Healthcare · Biotechnology · US
$15.52
+6.37%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | 68.0K | 97.0K | — | — | — |
| Gross Profit | (68.0K) | (97.0K) | — | — | — |
| Operating Expenses | |||||
| R&D Expense | 41.9M | 46.6M | 14.3M | 15.4M | 26.2M |
| SG&A Expense | 22.8M | 21.2M | 16.0M | 24.9M | 18.9M |
| General & Admin Expense | 11.5M | — | 16.0M | 24.9M | 18.9M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | 51.7M | — | — |
| Total Operating Expenses | 64.7M | 67.8M | 82.0M | 40.3M | 45.1M |
| Cost and Expenses | 64.8M | 67.9M | 82.0M | 40.3M | 45.1M |
| Operating Income (EBIT) | (64.8M) | (67.9M) | (82.0M) | (40.3M) | (45.1M) |
| Non-Operating | |||||
| Interest Income | 3.7M | 8.3M | 8.1M | 4.6M | 1.4M |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | 3.7M | 8.3M | 8.1M | 4.6M | 1.4M |
| Other Non-Op Income/Expense | 7.1M | 8.0M | 8.1M | 5.2M | (109.0K) |
| Non-Operating Income (excl Interest) | (5.3M) | (8.0M) | (51.7M) | (5.2M) | 109.0K |
| EBT (Pre-Tax Income) | (57.6M) | (59.9M) | (73.9M) | (35.1M) | (45.2M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (57.6M) | (59.9M) | (73.9M) | (35.1M) | (45.2M) |
| Earnings from Cont. Ops | (57.6M) | (59.9M) | (73.9M) | (35.1M) | (45.2M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (57.6M) | (59.9M) | (73.9M) | (35.1M) | (45.2M) |
| Per Share | |||||
| Basic EPS | ($0.83) | ($0.88) | ($1.53) | ($1.30) | ($1.72) |
| Diluted EPS | ($0.83) | ($0.88) | ($1.53) | ($1.30) | ($1.72) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 76.2M | 67.8M | 48.2M | 27.0M | 26.3M |
| Diluted Shares Outstanding | 76.2M | 67.8M | 48.2M | 27.0M | 26.3M |
| Profitability Metrics | |||||
| EBITDA | (59.4M) | (59.8M) | (30.4M) | (35.1M) | (45.2M) |
| D&A | 130.0K | 97.0K | — | — | — |
| EBIT | (59.5M) | (59.9M) | (30.4M) | (35.1M) | (45.2M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026